Genetic variability in CYP2A6 and the pharmacokinetics of nicotine (Q36989832)

17 August 2017

1 reference

title

Genetic variability in CYP2A6 and the pharmacokinetics of nicotine (English)

1 reference

17 August 2017

1 reference

Jill C Mwenifumbo

1

1 reference

PubMed ID

17979512

17 August 2017

Rachel F Tyndale

series ordinal

2

1 reference

17 August 2017

1 October 2007

1 reference

17 August 2017

1 reference

17 August 2017

8

1 reference

17 August 2017

10

1 reference

17 August 2017

1385-1402

1 reference

Nicotine-containing chewing gum in smoking cessation: a double blind trial with half year follow-up

17 August 2017

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Nicotine effects on adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Effects of acute nicotine administration on behavioral inhibition in adolescents with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Acute nicotine effects on auditory sensory memory in tacrine-treated and nontreated patients with Alzheimer's disease: an event-related potential study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Chronic transdermal nicotine patch treatment effects on cognitive performance in age-associated memory impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Transdermal nicotine in PD: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Excitability of motor cortex inhibitory circuits in Tourette syndrome before and after single dose nicotine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Clinical and attentional effects of acute nicotine treatment in Tourette's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Preliminary observations of oral nicotine therapy for inflammatory bowel disease: an open-label phase I-II study of tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Metabolism of nicotine to cotinine studied by a dual stable isotope method.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Three haplotypes associated with CYP2A6 phenotypes in Caucasians

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Deficient C-oxidation of nicotine continued.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

The significance of the homozygous CYP2A6 deletion on nicotine metabolism: a new genotyping method of CYP2A6 using a single PCR-RFLP

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

CYP2A6*6, a novel polymorphism in cytochrome p450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

CYP2A6 genotype and the metabolism and disposition kinetics of nicotine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

3'-UTR polymorphism in the human CYP2A6 gene affects mRNA stability and enzyme expression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

A nicotine C-oxidase gene (CYP2A6) polymorphism important for promoter activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Polymorphic NF-Y dependent regulation of human nicotine C-oxidase (CYP2A6).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Slower metabolism and reduced intake of nicotine from cigarette smoking in Chinese-Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Metabolism and disposition kinetics of nicotine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Within-subject variation of the salivary 3HC/COT ratio in regular daily smokers: prospects for estimating CYP2A6 enzyme activity in large-scale surveys of nicotine metabolic rate.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Prediction methods for nicotine clearance using cotinine and 3-hydroxy-cotinine spot saliva samples II. Model application.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Nicotine metabolism and CYP2A6 activity in a population of black African descent: impact of gender and light smoking.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Gender differences in tobacco smoking: higher relative exposure to smoke than nicotine in women

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Female sex and oral contraceptive use accelerate nicotine metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Accelerated metabolism of nicotine and cotinine in pregnant smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Effects of cigarette smoking and carbon monoxide on nicotine and cotinine metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Inactivation of CYP2A6 and CYP2A13 during nicotine metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Drug interaction potential of soy extract and Panax ginseng

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Metabolism of nicotine and cotinine by human cytochrome P450 2A13.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Expression of CYP2A genes in human liver and extrahepatic tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Analysis of Human Cytochrome P450 Catalytic Activities and Expression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

CYP2B6 genotype does not alter nicotine metabolism, plasma levels, or abstinence with nicotine replacement therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Comparison of Effect on Tobacco Consumption and Carbon Monoxide Absorption of Changing to High and Low Nicotine Cigarettes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Decreasing smoking behaviour and risk through CYP2A6 inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Effectiveness of the 4-mg dose of nicotine polacrilex for the initial treatment of high-dependent smokers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

The role of CYP2A6 in the emergence of nicotine dependence in adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Whole deletion of CYP2A6 gene (CYP2A6AST;4C) and smoking behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Limitation of cigarette consumption by CYP2A6*4, *7 and *9 polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

A meta-analytic review of the CYP2A6 genotype and smoking behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

The genetic basis for smoking behavior: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Approaches to cancer prevention based on an understanding of N-nitrosamine carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

DNA adduct formation from tobacco-specific N-nitrosamines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Environment and cancer: who are susceptible?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Genetic polymorphism of CYP2A6 in relation to cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Genetic variation of CYP2A6, smoking, and risk of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Novel human CYP2A6 alleles confound gene deletion analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Homologous unequal cross-over within the human CYP2A gene cluster as a mechanism for the deletion of the entire CYP2A6 gene associated with the poor metabolizer phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Characterization of a genotype previously designated as CYP2A6 D-type: CYP2A6*4B, another entire gene deletion allele of the CYP2A6 gene in Japanese

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

CYP2A6 polymorphisms in Malays, Chinese and Indians.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Inter-gene correlation on oligonucleotide arrays: how much does normalization matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

CYP2A6, MAOA, DBH, DRD4, and 5HT2A genotypes, smoking behaviour and cotinine levels in 1518 UK adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

High prevalence of cytochrome P450 2A6*1A alleles in a black African population of Ghana

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

In vivo Evaluation of Coumarin and Nicotine as Probe Drugs to Predict the Metabolic Capacity of CYP2A6 Due to Genetic Polymorphism in Thais

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.10.1385

10.2217/14622416.8.10.1385

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

17979512